Literature DB >> 28566532

Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasms.

Roberto Valente1, Alastair J Hayes2, Sven-Petter Haugvik3, Per Hedenström4, Darko Siuka5, Emilie Korsæth3, Daniel Kämmerer6, Stuart M Robinson7, Patrick Maisonneuve8, Gianfranco Delle Fave1, Bjorn Lindkvist4, Gabriele Capurso9.   

Abstract

Pancreatic neuroendocrine neoplasms (PNENs) represent 10% of all pancreatic tumors by prevalence. Their incidence has reportedly increased over recent decades in parallel with that of pancreatic adenocarcinoma. PNENs are relatively rare, and of the few institutions that have published potential risk factors, findings have been heterogeneous. Our objective was to investigate the association between potential risk and protective factors for the occurrence of sporadic PNENs across a European population from several institutions. A multinational European case-control study was conducted to examine the association of selected environmental, family and medical exposure factors using a standardized questionnaire in face-to-face interviews. A ratio of 1:3 cases to controls were sex and age matched at each study site. Adjusted univariate and multivariate logistic regression analysis were performed for statistically significant factors. The following results were obtained: In 201 cases and 603 controls, non-recent onset diabetes (OR 2.09, CI 1.27-3.46) was associated with an increased occurrence of PNENs. The prevalence of non-recent onset diabetes was higher both in cases with metastatic disease (TNM stage III-IV) or advanced grade (G3) at the time of diagnosis. The use of metformin in combination with insulin was also associated with a more aggressive phenotype. Drinking coffee was more frequent in cases with localized disease at diagnosis. Our study concluded that non-recent onset diabetes was associated with an increased occurrence of PNENs and the combination of metformin and insulin was consistent with a more aggressive PNEN phenotype. In contrast to previous studies, smoking, alcohol and first-degree family history of cancer were not associated with PNEN occurrence.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  gastrinomas; insulinomas; neuroendocrine neoplasms; pancreas; risk factors

Mesh:

Year:  2017        PMID: 28566532     DOI: 10.1530/ERC-17-0040

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  10 in total

1.  Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.

Authors:  Giovanna Muscogiuri; Barbara Altieri; Manuela Albertelli; Andrea Dotto; Roberta Modica; Luigi Barrea; Giuseppe Fanciulli; Tiziana Feola; Roberto Baldelli; Rosaria Maddalena Ruggeri; Marco Gallo; Valentina Guarnotta; Pasqualino Malandrino; Erika Messina; Mary Anna Venneri; Elisa Giannetta; Diego Ferone; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2020-05-28       Impact factor: 3.633

Review 2.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

3.  Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.

Authors:  T Feola; G Puliani; F Sesti; R Modica; R Centello; R Minotta; G Cannavale; S Di Meglio; V Di Vito; R Lauretta; M Appetecchia; A Colao; A Lenzi; A M Isidori; A Faggiano; E Giannetta
Journal:  J Endocrinol Invest       Date:  2022-01-18       Impact factor: 4.256

4.  Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Ana P Santos; Ana C Santos; Clara Castro; Luís Raposo; Sofia S Pereira; Isabel Torres; Rui Henrique; Helena Cardoso; Mariana P Monteiro
Journal:  Cancers (Basel)       Date:  2018-08-27       Impact factor: 6.639

5.  The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation-wide cancer registry-based study from Taiwan.

Authors:  Jeffrey S Chang; Li-Tzong Chen; Yan-Shen Shan; Pei-Yi Chu; Chia-Rung Tsai; Hui-Jen Tsai
Journal:  Cancer Med       Date:  2018-09-27       Impact factor: 4.452

6.  Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome.

Authors:  Ana P Santos; Clara Castro; Luís Antunes; Rui Henrique; M Helena Cardoso; Mariana P Monteiro
Journal:  J Clin Med       Date:  2019-09-17       Impact factor: 4.241

7.  Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Luigi Barrea; Giovanna Muscogiuri; Roberta Modica; Barbara Altieri; Gabriella Pugliese; Roberto Minotta; Antongiulio Faggiano; Annamaria Colao; Silvia Savastano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-18       Impact factor: 5.555

8.  Adult pancreatoblastoma: a case report.

Authors:  Jianchun Li; Chengzhong Peng; Xiaoming Fan; Ligang Wang; Jing Wang
Journal:  J Int Med Res       Date:  2021-08       Impact factor: 1.671

9.  Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis.

Authors:  Wence Zhou; Xinlong Chen; Qigang Fan; Haichuan Yu; Wenkai Jiang
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

10.  Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study.

Authors:  Luca Giraldi; Alessia Vecchioni; Stefania Boccia; Guido Rindi; Greta Carioli; Mirna Bilotta; Stefano La Rosa; Andrea Imperatori; Marco Volante; Maria Pia Brizzi; Frediano Inzani; Gianluigi Petrone; Giovanni Schinzari; Antonio Bianchi; Stefano Margaritora; Sergio Alfieri; Carlo La Vecchia
Journal:  Endocrine       Date:  2020-08-31       Impact factor: 3.633

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.